
Overview
NanoGroup SA is building a biotechnology group and developing projects in nanotechnology for medicine. Its projects include NanOX Recovery Box, NanOX 4 Kidney, AUX-001, and a pipeline with dextran conjugates and aptamers. The company also lists development milestones such as non-GLP studies, GMP batch production, and CE certification.
Financials
Revenue history (in k)
Filing timeliness
2 of 6 financial statements were filed late (the longest delay 45 days for 2021). All were audited by a statutory auditor.
- 202514/07/2026
- 202414/07/2025
- 202305/08/2024
- 202211/07/2023
- 202129/08/2022
- 202002/07/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Stock quotes
- Open
- PLN 2.03
- High
- PLN 2.07
- Low
- PLN 2.02
- Volume
- 85.1K
- Avg. vol.
- 59.1K
- Market cap
- PLN 86.32M
- P/E ratio
- –
- EPS
- -PLN 0.36
- Shares outstanding
- 42.63M
- 52-week
- PLN 1.98 – 2.30
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLNNGRP00011
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q3 2026 | USD -33.77k | USD -1.36m | USD -1.33m |
| Q2 2026 | USD 33.77k | USD -1.19m | USD -1.16m |
| Q1 2026 | USD -1.89k | USD -613.99k | USD -604.27k |
| Q4 2025 | USD 1.76k | USD -972.12k | USD -963.84k |
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.
Results vs industry
News

Next stage of NanOX 4 Kidney development. Preclinical studies started in Spain

NanoGroup S.A. published the Exclusion Document related to the offer of Series O shares for the transaction with Auxilius Pharma S.A.

„BUY” recommendation for NanoGroup S.A.

NanoGroup at the 17th Congress of the Polish Transplantation Society – NanOX technology at the center of discussion on the future of organ perfusion

Auxilius Pharma: key FDA feedback ahead of IND application for AUX-001

NanoSanguis SA: Innovative bioadsorbers selected for co-funding
Industry
Offer
- Preclinical testing
- Respiratory gas transport system
- Blood substitute
- Nanocapsules for targeted therapy
- Radioisotopes for diagnosis and treatment
Websites
- nanogroup.euStrona główna – Nanotechnologia w medycynie – NanoGroup SAWordPress 7.1Google AnalyticsGoogle Tag ManagerYoast SEOWWPMLNginx
Job offers
The company has its own careers page: nanogroup.eu/kontakt.
Authorized Representatives
Manner of representation
The following persons are authorized to make declarations of will on behalf of the company: in the case of a one-person management board, the President of the Management Board; in the case of a multi-member management board, two members of the management board or a member of the management board jointly with a commercial proxy.
Supervisory board
Beneficial owners
Nanogroup is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Doto Medical sp. z o.o. | 21,907.08 USD | 100% |
Capital group
| Name | Ownership |
|---|---|
Startventure@Poland Sp. z o.o. | 6.15% |
Grupa Kapitałowa NanoGroup SA | 7.17% |
| 41% |
Bank accounts
Registered as a VAT taxpayer on 2017-07-20.
63 1090 1870 0000 0001 3614 6531
61 1090 1870 0000 0001 4121 1228
61 1090 1870 0000 0001 3350 9428
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 21, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $4$4 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jun 23, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | Prezydent Miasta Stołecznego Warszawy | |
| Apr 28, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1$1 | Prezes Zakładu Ubezpieczeń Społecznych |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| JJP Biologics sp. z o.o. | $4,998,735.31 | jjpbiologics.com | ||
| Aslab Science P.S.A. | $1,504,132.17 | aslabsci.com | ||
| Scope Fluidics S.A. | $1,264,188.85 | scopefluidics.com | ||
| Śląski Park Technologii Medycznych Kardio-Med Silesia sp. z o.o. | $969,037.30 | kmptm.pl | ||
| Bioresearch Group sp. z o.o. | $776,186.19 | bioresearch.pl | ||
| Simbec-Orion (Pol) sp. z o.o. | $631,143.10 | simbecorion.com | ||
| Precisionlife Poland sp. z o.o. | $617,020.34 | precisionlife.com | ||
| MDR Regulator sp. z o.o. | $377,079.69 | pureclinical.eu | ||
| Medicofarma Biotech S.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Nanosanguis S.A. | $192,701.50 | nanosanguis.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-03-31 | Share capital increase (32,813,238.00 PLN → 42,628,988.00 PLN) | |
| 2025-10-14 | Share capital increase (32,164,563.00 PLN → 32,813,238.00 PLN) | |
| 2025-04-09 | Share capital increase (32,158,853.00 PLN → 32,164,563.00 PLN) | |
| 2024-12-10 | Share capital increase (28,654,093.00 PLN → 32,158,853.00 PLN) | |
| 2024-10-10 | Share capital increase (25,558,854.00 PLN → 28,654,093.00 PLN) |
FAQ
Last updated: 2026-10-07